The Safe Supply Ecosystem
At the core of our strategy is a diversified portfolio of companies and investments encompassing equity, debt, and partnerships that stretch across the entire drug reform value chain.
The foundation of every instance of drug policy reform has been to ensure that all products meet analytical quality and testing requirements. Our first investments are in labs positioned to be at the forefront of testing for the third wave.
More Investments Coming Soon
We’ve also developed a proprietary pipeline of early-stage companies that have strong management teams and well-designed business strategies that will play a pivotal role in the burgeoning safe supply ecosystem.
We expect to execute on many of these opportunities over the next 6 – 12 months.